AIM: Tamoxifen biotransformation to endoxifen, a potent antiestrogen, is catalyzed by CYP2D6. In addition, CYP2C19 and SULT1A1 have also been implicated in the metabolism of tamoxifen. We sought to evaluate the importance of SULT1A1 copy number and CYP2C19*17 on disease-free survival (DFS) in postmenopausal women randomized to tamoxifen monotherapyin North Central Cancer Treatment Group 89-30-52 from January 1991 to April 1995. MATERIALS & METHODS: We extracted DNA from paraffin-embedded tumors and determined tumor SULT1A1 copy number and CYP2C19*17 genotype. The association of genotype with DFS was determined using the log-rank test. Multivariate cox modeling was performed using traditional prognostic factors, as well as CYP2D6 genotype. SULT1A1 copy number and CYP2C19*17 genotype was determined in 190 out of 256 patients (95% Caucasian). RESULTS: The median follow-up for living patients was 14 years. DFS did not differ according to SULT1A1 copy number (p = 0.482) or CYP2C19*17 genotype (p = 0.667). Neither SULT1A1 copy number or CYP2C19*17 genotype was associated with disease recurrence in this cohort. CONCLUSION: Future studies are needed to identify whether other genetic and environmental factors which affect tamoxifen metabolism are associated with tamoxifen clinical outcomes.
RCT Entities:
AIM: Tamoxifen biotransformation to endoxifen, a potent antiestrogen, is catalyzed by CYP2D6. In addition, CYP2C19 and SULT1A1 have also been implicated in the metabolism of tamoxifen. We sought to evaluate the importance of SULT1A1 copy number and CYP2C19*17 on disease-free survival (DFS) in postmenopausal women randomized to tamoxifen monotherapy in North Central Cancer Treatment Group 89-30-52 from January 1991 to April 1995. MATERIALS & METHODS: We extracted DNA from paraffin-embedded tumors and determined tumorSULT1A1 copy number and CYP2C19*17 genotype. The association of genotype with DFS was determined using the log-rank test. Multivariate cox modeling was performed using traditional prognostic factors, as well as CYP2D6 genotype. SULT1A1 copy number and CYP2C19*17 genotype was determined in 190 out of 256 patients (95% Caucasian). RESULTS: The median follow-up for living patients was 14 years. DFS did not differ according to SULT1A1 copy number (p = 0.482) or CYP2C19*17 genotype (p = 0.667). Neither SULT1A1 copy number or CYP2C19*17 genotype was associated with disease recurrence in this cohort. CONCLUSION: Future studies are needed to identify whether other genetic and environmental factors which affect tamoxifen metabolism are associated with tamoxifen clinical outcomes.
Authors: Susan Nowell; Carol Sweeney; Maria Winters; Angie Stone; Nicholas P Lang; Laura F Hutchins; Fred F Kadlubar; Christine B Ambrosone Journal: J Natl Cancer Inst Date: 2002-11-06 Impact factor: 13.506
Authors: T E Mürdter; W Schroth; L Bacchus-Gerybadze; S Winter; G Heinkele; W Simon; P A Fasching; T Fehm; M Eichelbaum; M Schwab; H Brauch Journal: Clin Pharmacol Ther Date: 2011-03-30 Impact factor: 6.875
Authors: Yan Jin; Zeruesenay Desta; Vered Stearns; Bryan Ward; Herbert Ho; Kyung-Hoon Lee; Todd Skaar; Anna Maria Storniolo; Lang Li; Adjei Araba; Rebecca Blanchard; Anne Nguyen; Lynda Ullmer; Jill Hayden; Suzanne Lemler; Richard M Weinshilboum; James M Rae; Daniel F Hayes; David A Flockhart Journal: J Natl Cancer Inst Date: 2005-01-05 Impact factor: 13.506
Authors: Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506
Authors: Michael D Johnson; Hong Zuo; Kyung-Hoon Lee; Joseph P Trebley; James Michael Rae; Ross V Weatherman; Zeruesanay Desta; David A Flockhart; Todd C Skaar Journal: Breast Cancer Res Treat Date: 2004-05 Impact factor: 4.872
Authors: Raymon Vijzelaar; Mariana R Botton; Lisette Stolk; Suparna Martis; Robert J Desnick; Stuart A Scott Journal: Pharmacogenomics Date: 2018-05-23 Impact factor: 2.533
Authors: Daniel J Klein; Caroline F Thorn; Zeruesenay Desta; David A Flockhart; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2013-11 Impact factor: 2.089
Authors: L Weng; D Ziliak; H K Im; E R Gamazon; S Philips; A T Nguyen; Z Desta; T C Skaar; D A Flockhart; R S Huang Journal: Ann Oncol Date: 2013-03-18 Impact factor: 32.976
Authors: Jennifer Gjerde; Sara Gandini; Aliana Guerrieri-Gonzaga; Line L Haugan Moi; Valentina Aristarco; Gunnar Mellgren; Andrea Decensi; Ernst A Lien Journal: Breast Cancer Res Treat Date: 2012-05-05 Impact factor: 4.872